Market Report, "Uzbekistan Pharmaceuticals & Healthcare Report Q1 2016", published

Uzbekistan's healthcare system will continue to suffer from human resource constraints, impeding improvements in healthcare outcomes in the long term. Drugmakers focused on infectious and communicable diseases can expect to see continued revenue growth given the significant burden of diseases such as HIV/AIDS, tuberculosis and respiratory diseases, although we expect that this will be moderated by the low affordability of pharmaceuticals and the limited capacity of the Uzbek healthcare system to purchase medicines for the population.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/1109976_uzbekistan_pharmaceuticals.aspx?afid=301

Pharmaceuticals: UZS2.21trn (USD956mn) in 2014 to UZS2.78trn (USD1.03bn) in 2015; 26.1% in local currency terms and 7.4% in US dollar terms. Forecast unchanged from last quarter.
Healthcare: UZS8.84trn (USD3.83bn) in 2014 to UZS10.54trn (USD3.89bn) in 2015; 19.2% in local currency terms and 1.5% in US dollar terms. Forecast unchanged from last quarter.

The Uzbekistan Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Uzbekistan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Uzbekistan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Uzbekistan, to test other views - a key input for successful budgeting and strategic business planning in the Uzbekistani pharmaceutical and healthcare market.
* Target business opportunities and risks in the Uzbekistani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Uzbekistan.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

* Healthcare:

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- France Pharmaceuticals & Healthcare Report Q1 2016
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016